New Delhi: Drug majors Roche India and Cipla announced on Monday the launch of Roche’s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of moderate or mild coronavirus patients who are at high risk. This is also the same drug that was used on former US President Donald Trump last year when he contracted COVID-19.
“The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients,” Cipla and Roche said in a joint statement.
Cipla said that they will be distributing the product by leveraging its strong distribution strengths across India.
The value for each jab [a combined dose of 1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] is set at Rs 59,750 including taxes. However, the maximum retail price for Roche’s Antibody Cocktail (each pack can treat two patients) is set for Rs 1,19,500 inclusive of all taxes
According to the statement, the drug will be made available through all leading hospitals and COVID-19 treatment centres.
Recently, the Central Drugs Standards Control Organisation (CDSCO) had provided an emergency use authorisation (EUA) for the Antibody Cocktail (Casirivimab and Imdevimab) in India. The above-mentioned dug also received a EUA in the US and several EU nations.
“Roche is deeply committed to supporting the ongoing efforts to combat the COVID-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalization, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens,” said V Simpson Emmanuel, Managing Director and CEO, Roche Pharma India.